Denali Therapeutics
Mark leads Denali's Intellectual Property Team, and is the Legal Team lead on strategic transactions and other corporate development matters, bringing more than sixteen years of legal experience representing biotech and pharma companies.
Prior to Denali, Mark was Senior Director, Associate General Counsel, at Genentech Inc., where he was responsible for intellectual property matters across multiple therapeutic areas. Prior to that, he held positions at Allergan Inc., and the international law firm Jones Day where he represented a variety of biotech and pharma clients. Mark has a J.D. from the University of San Diego School of Law and B.S. and M.S. degrees in Chemistry from the University of California, San Diego.
Denali Therapeutics
6 followers
Denali Therapeutics is dedicated to defeating neurodegenerative diseases by breaking through historical barriers in scientific research and clinical development in order to deliver safe and effective medicines to patients and families.